OVERVIEW

Medical Crossfire®: Critical Conversations Between Ovarian Cancer Centers of Excellence and the Community is organized by Physicians' Education Resource, LLC (PER).

Release Date: January 31, 2020
Expiration Date: January 31, 2021

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hour(s).

Activity Overview:
PARP inhibitors have demonstrated marked efficacy in the treatment of patients with ovarian cancer in both upfront maintenance and later-line settings and have transformed treatment of women with ovarian cancer in recent years. Recent trials have also reported promising results with PARP inhibitors in place of single-agent chemotherapy, as well as in combination with VEGF inhibitors and PD-1 inhibitors. Moreover, histologic and molecular testing has also developed in recent years and is important for guiding treatment decision-making in ovarian cancer and for improving outcomes for patients.

Despite these advances and expansion of treatment options, barriers remain to the adoption of available PARP inhibitor therapies and combination strategies in the community setting. These include lack of knowledge of family medical history, awareness of genetic services, financial anxiety or insurance limitations, inadequate coordination of referrals, lack of knowledge of clinical guidelines, among others.

This activity brings key clinical experts in the medical management of ovarian cancer from both academic cancer centers and community-based hospitals together for an in-depth discussion on how to best apply treatment protocols in the community healthcare setting. The expert panel discusses recent practice-changing trial data and places these findings in the context of real-world clinical situations that allows for clinical decision-making in multidisciplinary teams.

Benefits of Participating:
• Hear the experts describe their use of available diagnostic strategies and treatment options for patient with ovarian cancer
• Review the latest clinical trial evidence for PARP inhibition, anti-angiogenesis, checkpoint blockade and combination strategies to optimize decision making in ovarian cancer and to identify appropriate clinical trials for your patients
• Learn about barriers to implementing current diagnostic and treatment options for ovarian cancer patients faced by practitioners in the community
• Apply the latest data to select treatments with the goal of minimizing adverse events and reducing toxicity in patients with ovarian cancer

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Choose appropriate diagnostic strategies and treatment options when using PARP inhibitors in clinical practice for the treatment of patients with ovarian cancer
• Describe the rationale for ongoing trials using PARP inhibitors and combination therapies in earlier stages and heavily pretreated patients with ovarian cancer
• Evaluate patients eligible for clinical trials and how to optimize patient communication and the referral process, to increase clinical trial enrollment
• Define and explain adverse events commonly associated with PARP inhibitors to optimize clinical outcomes of ovarian cancer patients